vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Fortrea Holdings Inc. (FTRE). Click either name above to swap in a different company.

Fortrea Holdings Inc. is the larger business by last-quarter revenue ($660.5M vs $487.7M, roughly 1.4× CLOVER HEALTH INVESTMENTS, CORP.). Fortrea Holdings Inc. runs the higher net margin — -4.9% vs -10.1%, a 5.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -5.2%). Fortrea Holdings Inc. produced more free cash flow last quarter ($121.6M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -0.1%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.

CLOV vs FTRE — Head-to-Head

Bigger by revenue
FTRE
FTRE
1.4× larger
FTRE
$660.5M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+50.0% gap
CLOV
44.7%
-5.2%
FTRE
Higher net margin
FTRE
FTRE
5.2% more per $
FTRE
-4.9%
-10.1%
CLOV
More free cash flow
FTRE
FTRE
$190.6M more FCF
FTRE
$121.6M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-0.1%
FTRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
FTRE
FTRE
Revenue
$487.7M
$660.5M
Net Profit
$-49.3M
$-32.5M
Gross Margin
Operating Margin
-10.1%
-2.1%
Net Margin
-10.1%
-4.9%
Revenue YoY
44.7%
-5.2%
Net Profit YoY
-123.2%
46.9%
EPS (diluted)
$-0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
FTRE
FTRE
Q4 25
$487.7M
$660.5M
Q3 25
$496.6M
$701.3M
Q2 25
$477.6M
$710.3M
Q1 25
$462.3M
$651.3M
Q4 24
$337.0M
$697.0M
Q3 24
$331.0M
$674.9M
Q2 24
$356.3M
$662.4M
Q1 24
$346.9M
$662.1M
Net Profit
CLOV
CLOV
FTRE
FTRE
Q4 25
$-49.3M
$-32.5M
Q3 25
$-24.4M
$-15.9M
Q2 25
$-10.6M
$-374.9M
Q1 25
$-1.3M
$-562.9M
Q4 24
$-22.1M
$-61.2M
Q3 24
$-9.2M
$-27.9M
Q2 24
$7.4M
$-138.4M
Q1 24
$-19.2M
$-101.0M
Gross Margin
CLOV
CLOV
FTRE
FTRE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
CLOV
CLOV
FTRE
FTRE
Q4 25
-10.1%
-2.1%
Q3 25
-4.9%
-1.2%
Q2 25
-2.2%
-46.5%
Q1 25
-0.3%
-79.9%
Q4 24
-6.4%
-8.0%
Q3 24
-2.7%
-2.7%
Q2 24
2.0%
-7.7%
Q1 24
-6.5%
-5.6%
Net Margin
CLOV
CLOV
FTRE
FTRE
Q4 25
-10.1%
-4.9%
Q3 25
-4.9%
-2.3%
Q2 25
-2.2%
-52.8%
Q1 25
-0.3%
-86.4%
Q4 24
-6.6%
-8.8%
Q3 24
-2.8%
-4.1%
Q2 24
2.1%
-20.9%
Q1 24
-5.5%
-15.3%
EPS (diluted)
CLOV
CLOV
FTRE
FTRE
Q4 25
$-0.25
Q3 25
$-0.17
Q2 25
$-4.14
Q1 25
$-6.25
Q4 24
$-0.68
Q3 24
$-0.31
Q2 24
$-1.55
Q1 24
$-1.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
FTRE
FTRE
Cash + ST InvestmentsLiquidity on hand
$78.3M
$174.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$563.5M
Total Assets
$541.0M
$2.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
FTRE
FTRE
Q4 25
$78.3M
$174.6M
Q3 25
$131.3M
Q2 25
$81.2M
Q1 25
$101.6M
Q4 24
$194.5M
$118.5M
Q3 24
$288.0M
$105.3M
Q2 24
$254.8M
$126.2M
Q1 24
$208.3M
$92.8M
Stockholders' Equity
CLOV
CLOV
FTRE
FTRE
Q4 25
$308.7M
$563.5M
Q3 25
$340.9M
$580.8M
Q2 25
$344.2M
$589.2M
Q1 25
$336.1M
$858.8M
Q4 24
$341.1M
$1.4B
Q3 24
$342.2M
$1.5B
Q2 24
$324.9M
$1.5B
Q1 24
$292.5M
$1.6B
Total Assets
CLOV
CLOV
FTRE
FTRE
Q4 25
$541.0M
$2.7B
Q3 25
$559.7M
$2.7B
Q2 25
$575.0M
$2.8B
Q1 25
$583.7M
$3.1B
Q4 24
$580.7M
$3.6B
Q3 24
$653.0M
$3.7B
Q2 24
$674.2M
$3.6B
Q1 24
$671.8M
$4.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
FTRE
FTRE
Operating Cash FlowLast quarter
$-66.9M
$129.1M
Free Cash FlowOCF − Capex
$-69.0M
$121.6M
FCF MarginFCF / Revenue
-14.1%
18.4%
Capex IntensityCapex / Revenue
0.4%
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$88.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
FTRE
FTRE
Q4 25
$-66.9M
$129.1M
Q3 25
$12.1M
$86.8M
Q2 25
$5.4M
$21.8M
Q1 25
$-16.3M
$-124.2M
Q4 24
$34.8M
$17.1M
Q3 24
$50.0M
$-2.4M
Q2 24
$44.8M
$273.7M
Q1 24
$25.9M
$-25.6M
Free Cash Flow
CLOV
CLOV
FTRE
FTRE
Q4 25
$-69.0M
$121.6M
Q3 25
$11.4M
$79.5M
Q2 25
$4.8M
$14.3M
Q1 25
$-16.5M
$-127.1M
Q4 24
$33.3M
$13.9M
Q3 24
$49.6M
$-10.6M
Q2 24
$44.4M
$262.5M
Q1 24
$25.5M
$-34.9M
FCF Margin
CLOV
CLOV
FTRE
FTRE
Q4 25
-14.1%
18.4%
Q3 25
2.3%
11.3%
Q2 25
1.0%
2.0%
Q1 25
-3.6%
-19.5%
Q4 24
9.9%
2.0%
Q3 24
15.0%
-1.6%
Q2 24
12.5%
39.6%
Q1 24
7.3%
-5.3%
Capex Intensity
CLOV
CLOV
FTRE
FTRE
Q4 25
0.4%
1.1%
Q3 25
0.1%
1.0%
Q2 25
0.1%
1.1%
Q1 25
0.0%
0.4%
Q4 24
0.5%
0.5%
Q3 24
0.1%
1.2%
Q2 24
0.1%
1.7%
Q1 24
0.1%
1.4%
Cash Conversion
CLOV
CLOV
FTRE
FTRE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons